Key points

In infants

• The mandatory meningococcal ACWY vaccination program, implemented on January 1, 2025, for infants following an increase in cases of invasive meningococcal infections of types W and Y, has resulted in high vaccination coverage, with nearly 89.3% of infants born in 2025 having received the first dose of the meningococcal ACWY vaccine. Among children born in 2024, before the replacement of the meningococcal C vaccine with the ACWY vaccine, 89.6% had received at least one dose of the tetravalent ACWY meningococcal vaccine by age 21 months. This vaccination coverage is slightly lower than that estimated in 2024 for meningococcal C. It should be noted that vaccination started with a monovalent C vaccine before January 1, 2025, in infants must be continued with a tetravalent ACWY vaccine.
• In 2025, the year the mandatory vaccination against meningococcal B was implemented for infants up to 2 years of age, vaccination coverage against these infections has increased significantly, with 70.0% of infants born in 2024 (aged 21 months) having received two doses (compared to 59.7% in 2024).
• Vaccination coverage for other mandatory infant vaccinations is generally very high, with levels close to the 95% target set by the World Health Organization (WHO). In particular, given the resurgence of measles virus circulation in France since 2024, it is important to note that vaccination coverage is sufficient to interrupt the spread of this highly contagious virus—which can lead to severe illness—if it reaches at least 95% with a complete vaccination schedule. The full vaccination schedule usually consists of two doses (or three doses if the first dose was received before 12 months of age). Systematic verification of vaccination status is essential for children and young adults.

In adolescents and young adults

• During adolescence and early adulthood, invasive meningococcal W and Y infections are increasingly being reported due to the implementation of mandatory vaccination for infants since 2025 and high levels of social interaction within these populations. Vaccination against meningococcal ACWY is recommended for adolescents, with catch-up vaccination for young adults. In 2025, only 20.3% of 11- to 14-year-olds and 10.0% of 15- to 24-year-olds had received a dose of this vaccine. Vaccination against meningococcal ACWY must be intensified in these age groups. The inclusion of this vaccination in campaigns conducted in middle schools starting in 2026 will help strengthen protection for young people against these infections. Efforts to improve vaccination coverage must continue in order to achieve herd immunity and reduce the circulation of meningococci in other age groups.
• Vaccination coverage against human papillomavirus (HPV) infections continues to increase, with 56.1% of 16-year-old girls and 34.2% of 16-year-old boys having received a full vaccination series. The gap in vaccination coverage between girls and boys continues to narrow. This progress is encouraging, but vaccination coverage remains insufficient to reduce the incidence of cancers linked to these infections. The annual launch of vaccination campaigns in middle schools and the extension of the vaccination recommendation to young women up to age 26 by 2025 should make it possible to reach the 80% target set by the 10-year strategy to combat cancers in girls and boys by 2030.

Vaccination uptake

According to the 2024 Santé publique France Barometer, vaccination uptake remains high in the region, particularly among young people, with 80.6% of 18- to 25-year-olds stating they are in favor of vaccination in general.